Anzeige
Mehr »
Login
Dienstag, 30.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Basin Uranium: Es geht los! Der Uran-Superzyklus ist gestartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0NJJ3 | ISIN: NO0010395577 | Ticker-Symbol: 65I
Frankfurt
29.04.24
08:09 Uhr
3,220 Euro
+0,050
+1,58 %
Branche
Maschinenbau
Aktienmarkt
Sonstige
1-Jahres-Chart
PHILLY SHIPYARD ASA Chart 1 Jahr
5-Tage-Chart
PHILLY SHIPYARD ASA 5-Tage-Chart
ACCESSWIRE
525 Leser
Artikel bewerten:
(2)

Philly Shipyard ASA: Philly Shipyard Wins Contract for Hospital Ship Design Study

PHILADELPHIA, PA / ACCESSWIRE / July 12, 2023 / Philly Shipyard, Inc. ("Philly Shipyard"), the sole operating subsidiary of Philly Shipyard ASA (Oslo:PHLY) today announced the contract award to conduct the T-AH(X) Hospital Ship Feasibility Study for Gibbs and Cox, a Leidos Inc. company. The six-month design study will cover a solution for preliminary designs to replace the two current hospital ships - USNS Mercy and USNS Comfort - owned by the U.S. Navy and operated by Military Sealift Command (MSC). Philly Shipyard will subcontract to Vard Marine Inc. ("VARD") to provide engineering and technical services for this effort.

"This contract win highlights our commitment to pursuing and securing work in the government market," said Steinar Nerbovik, Philly Shipyard President and CEO. "Along with our current commercial and government backlog of shipbuilding projects, we have completed previous design studies for the U.S. Navy and are very interested in pursuing government opportunities that fit our production delivery cycles and skill sets. We are excited and grateful to team up, once again, with Vard Marine on this important industry study."

Philly Shipyard and VARD will leverage design work performed as part of a special study completed for the U.S. Navy's Common Hull Auxiliary Multi-Mission Platform (CHAMP) program, which was won in 2019.

About Philly Shipyard

Philly Shipyard, Inc. (PSI) is a leading U.S. shipbuilder that is presently pursuing a mix of commercial and government work. It possesses a state-of-the-art shipbuilding facility and has earned a reputation as a preferred provider of oceangoing merchant vessels with a track record of delivering quality ships, having delivered around 50% of all large ocean-going Jones Act commercial ships since 2000. PSI is the sole operating subsidiary of Philly Shipyard ASA. Philly Shipyard ASA is listed on the Euronext Expand Oslo (Oslo: PHLY) and is majority-owned by Aker Capital AS, which in turn is wholly-owned by Aker ASA (Aker). Aker is an industrial investment company that exercises active ownership to create value. Aker has ownership interests in oil and gas, renewable energy and green technologies, maritime assets, marine biotechnology and industrial software, and its portfolio includes companies like Aker BP, Aker Horizons, Aker BioMarine, Cognite, and Aker Solutions. For more information about Philly Shipyard, visit www.phillyshipyard.com.

Media Contacts:

Philly Shipyard, Inc.
Matt Cassidy
215-875-8863
matthew.cassidy@phillyshipyard.com

SOURCE: Philly Shipyard ASA

View source version on accesswire.com:
https://www.accesswire.com/767371/Philly-Shipyard-Wins-Contract-for-Hospital-Ship-Design-Study

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2023 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.